Intra-Anally Administered Artesunate in Patients With High-Grade Anal Intraepithelial Neoplasia (AIN 2/3)
Status:
Completed
Trial end date:
2021-10-06
Target enrollment:
Participant gender:
Summary
This open label study investigates a novel non-surgical approach to the treatment of
HPV-associated anal intraepithelial neoplasia, using Artesunate suppositories.
Phase:
Phase 1
Details
Lead Sponsor:
Johns Hopkins University
Collaborators:
Frantz Medical Group Frantz Viral Therapeutics, LLC University of Wisconsin, Madison